论文部分内容阅读
目的:分析培美曲塞二钠联合卡铂治疗非小细胞型肺癌的临床效果。方法:选择该院附属医院收治的68例非小细胞型肺癌患者实行对比分析,其中34例患者采用吉西他滨联合卡铂治疗,为对照组;34例患者采用培美曲塞二钠联合卡铂治疗,为研究组,并对比两组临床效果。结果:研究组近期疗效的总缓解率为41.18%,远高于对照组的(17.65%,P<0.05);各项不良反应发生率的对比上,研究组均少于对照组(P<0.05)。结论:培美曲塞二钠联合卡铂治疗非小细胞型肺癌的近期临床疗效显著,能对患者的肿瘤病灶变化产生良好的控制作用,安全性较高,值得推广。
Objective: To analyze the clinical effect of pemetrexed disodium combined with carboplatin in the treatment of non-small cell lung cancer. Methods: A total of 68 non-small cell lung cancer patients admitted to the hospital affiliated hospital were compared. Among them, 34 patients were treated with gemcitabine combined with carboplatin as control group; 34 patients were treated with pemetrexed disodium combined with carboplatin , For the study group, and compared the clinical effect of two groups. Results: The overall response rate of the study group was 41.18%, which was significantly higher than that of the control group (17.65%, P <0.05). The incidences of adverse reactions in the study group were less than those in the control group (P <0.05) ). Conclusion: Pemetrexed disodium combined with carboplatin in the treatment of non-small cell lung cancer has obvious clinical efficacy in recent years, which can exert good control effect on the changes of tumor lesions in patients with high safety and is worth promoting.